Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
Last trade$8.01
Day change-$0.05 (-0.62%)
Day range$7.88 – $8.25
Volume2,204,308
Market cap$1.33B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.33B
Price / earnings
—
Price / book
-6.13×
Price / sales
3.23×
EV / sales
3.41×
EV / EBITDA
-19.4×
Profitability
Earnings per share
-$0.46
Return on assets
-8.64%
Return on equity
35.38%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-1.36×
Current ratio
2.15×
Quick ratio
2.09×
Cash ratio
0.67×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$244.08M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for NVAX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$68.3M
$56.7M
$139.51M
$147.14M
$70.45M
$239.24M
$666.66M
$88.31M
Cost of revenue
$23.49M
$14.25M
$30.7M
$22.1M
$21.5M
$15.33M
$14.12M
$36.67M
Gross profit
$44.81M
$42.45M
$108.82M
$125.04M
$48.95M
$223.92M
$652.54M
$51.64M
Selling, general and administrative
$23.65M
$26.67M
$28.78M
$34.12M
$31.66M
$43.61M
$48.09M
$78.34M
Research and development
$52.45M
$70.69M
$95.47M
$75.88M
$98.27M
$79.23M
$88.94M
$104.38M
Total operating expenses
$76.09M
$97.36M
$124.25M
$110.81M
$226.97M
$122.85M
$137.03M
$182.72M
Operating income
-$31.28M
-$54.91M
-$15.43M
$14.23M
-$178.02M
$101.07M
$515.51M
-$131.08M
Interest expense
-$5.4M
-$5.69M
-$4.9M
-$5.82M
-$5.48M
-$5.52M
-$5.72M
-$7.59M
Income before taxes
-$29.65M
-$51.68M
-$8.51M
$17.9M
-$203.04M
$107.45M
$519.85M
-$73.58M
Income taxes
$1.72M
$1.71M
$985K
$376K
-$657K
$946K
$1.2M
$7.45M
Net income
-$31.38M
-$53.39M
-$9.49M
$17.53M
-$202.38M
$106.51M
$518.65M
-$81.03M
Net income attributable to common shareholders
-$31.38M
-$53.39M
-$9.49M
$17.53M
-$202.38M
$106.51M
$518.65M
-$81.03M
EBITDA
-$28.23M
-$51.85M
-$12.37M
$20.16M
-$74.4M
$108.63M
$523.85M
-$118.56M
Basic earnings per share
-$0.19
-$0.32
-$0.06
$0.11
-$1.25
$0.66
$3.22
-$0.51
Diluted earnings per share
-$0.19
-$0.32
-$0.06
$0.10
-$1.25
$0.62
$2.93
-$0.57
Recent news
Company coverage with links to the original publishers.
Novavax has been a trending stock, but shares have declined 14% over the past month, underperforming the S&P 500's -3.3% decline. While the company shows strong earnings estimate revisions and has beaten consensus estimates in recent quarters, it carries a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the broader market. The stock is valued at par with peers and faces projected revenue declines of 58.4% and 42.4% for the current and next fiscal years, respectively.
Novavax reported Q3 2026 loss of 19 cents per share, beating estimates, with revenues of $68 million exceeding consensus. The company raised 2026 revenue guidance to $385-$415 million, primarily driven by a $125 million Sanofi milestone. Despite operational improvements and cost reductions, shares fell 8.2% as investors focused on the one-time nature of the milestone and dependence on a potential 2029 U.S. vaccine launch for profitability.
Novavax stock declined 3.09% to $9.40, underperforming the broader market which gained 0.7%. The vaccine maker has lost 8.75% over the past month and faces headwinds with expected quarterly revenue down 28.15% year-over-year to $50.61 million. However, consensus EPS estimates have shifted upward 16.88% over the past month, and the stock holds a Zacks Rank #3 (Hold) rating.
Biogen shares surged 5.3% to $253.84 driven by positive phase II data from its AMETHYST study for litifilimab in cutaneous lupus erythematosus, with phase III data expected in H1 2027. However, the company's consensus EPS estimate was revised 1.8% lower over the past month, which could limit further price appreciation. Novavax declined 9.3% to $9.99 with its EPS estimate revised down 8.1% over the past month.
Moderna's stock fell 18% after reports of a data leak regarding its personalized melanoma vaccine showed a 42% reduction in recurrence or death risk when paired with Merck's Keytruda—lower than Phase II results of 49%. The full Phase 3 results were scheduled for release on October 24, and the leaked figures fell short of market expectations despite the company's 600% gain in 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Dec 13, 2007
$2.125
Dec 31, 2007
unknown
Nov 13, 2007
$2.125
Nov 30, 2007
unknown
Oct 11, 2007
$2.125
Oct 31, 2007
unknown
Sep 13, 2007
$2.125
Sep 28, 2007
recurring
Aug 13, 2007
$2.125
Aug 31, 2007
recurring
Stock splits
Historical share-structure events and their execution dates.